Charting the molecular network of the drug target Bcr-Abl

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 18, 2009, Pages 7414-7419

  Brehme, Marc ^a   Hantschel, Oliver ^a   Colinge, Jacques ^a   Kaupe, Ines ^a   Planyavsky, Melanie ^a   Köcher, Thomas ^b   Mechtler, Karl ^b   Bennett, Keiryn L ^a   Superti Furga, Giulio ^a  

^a ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

^b RESEARCH INSTITUTE OF MOLECULAR PATHOLOGY   (Austria)

Author keywords

Chronic myeloid leukemia; Imatinib; Protein interaction network tyrosine kinase inhibitor

Indexed keywords

BCR ABL PROTEIN; CBL PROTEIN; CELL PROTEIN; CRK LIKE PROTEIN; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; PHOSPHOTYROSINE; PROTEIN P85; PROTEIN TYROSINE KINASE INHIBITOR; MULTIENZYME COMPLEX; PROTEIN KINASE INHIBITOR;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG TARGETING; HUMAN; HUMAN CELL; MASS SPECTROMETRY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; DRUG ANTAGONISM; METABOLISM; PROTEIN ANALYSIS;

CELL LINE; FUSION PROTEINS, BCR-ABL; HUMANS; MULTIENZYME COMPLEXES; PROTEIN INTERACTION MAPPING; PROTEIN KINASE INHIBITORS; PROTEOMICS;

EID: 66149095910     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0900653106     Document Type: Article

References (48)

1. Bleicher KH, Bohm HJ, Muller K, Alanine AI (2003) Hit and lead generation: Beyond high-throughput screening. Nat Rev Drug Discov 2:369-378.
2. Brown D, Superti-Furga G (2003) Rediscovering the sweet spot in drug discovery. Drug Discov Today 8:1067-1077.
3. Bouwmeester T, et al. (2004) A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 6:97-105.
4. Gavin AC, et al. (2006) Proteome survey reveals modularity of the yeast cell machinery. Nature 440:631-636.
5. Kuriyan J, Eisenberg D (2007) The origin of protein interactions and allostery in colocalization. Nature 450:983-990.
6. Bantscheff M, et al. (2007) Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat Biotechnol 25:1035-1044.
7. Rix U, et al. (2007) Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 110:4055-4063.
8. Evans WE, McLeod HL (2003) Pharmacogenomics: Drug disposition, drug targets, and side effects. N Engl J Med 348:538-549.
9. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target network. Nat Biotechnol 25:1119-1126.
10. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P (2008) Drug target identification using side-effect similarity. Science 321:263-266.
11. Wong S, Witte ON (2004) The BCR-ABL story: Bench to bedside and back. Annu Rev Immunol 22:247-306.
12. Daley GQ, Van Etten RA, Baltimore D (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science 247:824-830.
13. Van Etten RA (2007) Oncogenic signaling: New insights and controversies from chronic myeloid leukemia. J Exp Med 204:461-465.
14. Deininger M, Buchdunger E, Druker BJ (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 105:2640-2653.
15. Quintas-Cardama A, Kantarjian H, Cortes J (2007) Flying under the radar: The new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6:834-848.
16. Schiffer CA (2007) BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia. N Engl J Med 357:258-265.
17. O'Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242-2249.
18. Sattler M, Griffin JD (2003) Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40:4-10.
19. Salomon AR, et al. (2003) Profiling of tyrosine phosphorylation pathways in human cells using mass spectrometry. Proc Natl Acad Sci USA 100:443-448.
20. Steen H, Fernandez M, Ghaffari S, Pandey A, Mann M (2003) Phosphotyrosine mapping in Bcr/Abl oncoprotein using phosphotyrosine-specific immonium ion scanning. Mol Cell Proteomics 2:138-145.
21. Hantschel O, Superti-Furga G (2004) Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5:33-44.
22. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukemia. Nat Rev Cancer 5:172-183.
23. Schiff-Maker L, et al. (1986) Monoclonal antibodies specific for v-abl- and c-abl- encoded molecules. J Virol 57:1182-1186.
24. Hantschel O, et al. (2005) Structural basis for the cytoskeletal association of Bcr-Abl/ c-Abl. Mol Cell 19:461-473.
25. Kersey PJ, et al. (2004) The International Protein Index: An integrated database for proteomics experiments. Proteomics 4:1985-1988.
26. Schirle M, Heurtier MA, Kuster B (2003) Profiling core proteomes of human cell lines by one-dimensional PAGE and liquid chromatography-tandem mass spectrometry. Mol Cell Proteomics 2:1297-1305.
27. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116 -5121.
28. Pawson T (2007) Dynamic control of signaling by modular adaptor proteins. Curr Opin Cell Biol 19:112-116.
29. Zhao L, Vogt PK (2008) Class I PI3K in oncogenic cellular transformation. Oncogene 27:5486-5496.
30. Thien CB, Langdon WY (2001) Cbl: Many adaptations to regulate protein tyrosine kinases. Nat Rev Mol Cell Biol 2:294-307.
31. Wisniewski D, et al. (1999) A novel SH2-containing phosphatidylinositol 3,4,5- trisphosphate 5-phosphatase (SHIP-2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93:2707-2720.
32. Mikhailik A, et al. (2007) A phosphatase activity of Sts-1 contributes to the suppression of TCR signaling. Mol Cell 27:486-497.
33. Carpino N, et al. (2002) Identification, cDNA cloning, and targeted deletion of p70, a novel, ubiquitously expressed SH3 domain-containing protein. Mol Cell Biol 22:7491-7500.
34. Schade AE, et al. (2008) Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T cellactivation and proliferation. Blood 111:1366-1377.
35. Pendergast AM (2002) The Abl family kinases: Mechanisms of regulation and signaling. Adv Cancer Res 85:51-100.
36. Barilá D, Superti-Furga G (1998) An intramolecular SH3-domain interaction regulates c-Abl activity. Nat Genet 18:280-282.
37. Burckstummer T, et al. (2006) An efficient tandem affinity purification procedure for interaction proteomics in mammalian cells. Nat Methods 3:1013-1019.
38. Tong AH, et al. (2002) A combined experimental and computational strategy to define protein interaction networks for peptide recognition modules. Science 295:321-324.
39. Chen J, et al. (2007) SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl. Blood 109:778-785.
40. Sattler M, et al. (2002) Critical role for Gab2 in transformation by BCR/ABL. Cancer Cell 1:479 -492.
41. Hantschel O, Rix U, Superti-Furga G (2008) Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib. Leuk Lymphoma 49:615-619.
42. Ross PL, et al. (2004) Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol Cell Proteomics 3:1154-1169.
43. Gingras AC, Gstaiger M, Raught B, Aebersold R (2007) Analysis of protein complexes using mass spectrometry. Nat Rev Mol Cell Biol 8:645-654.
44. Taylor V, et al. (2000) 5′ phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol Cell Biol 20:6860-6871.
45. Hantschel O, et al. (2007) The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib. Proc Natl Acad Sci USA 104:13283-13288.
46. Shevchenko A, Wilm M, Vorm O, Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68:850-858.
47. Rappsilber J, Ishihama Y, Mann M (2003) Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. Anal Chem 75:663-670.
48. Hantschel O, et al. (2008) The chemokine IL-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in CML. Molecular Oncology2(3):272-281.